1.Miyamoto, S, Miyake, N, Jarskog, L, et al. 2012. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012; 17(12): 1206–1227.
2.Kahn, RS, Sommer, IE, Murray, RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015; 1: 15067.
3.Breier, A, Buchanan, RW, Kirkpatrick, B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 1994; 151(1): 20–26.
4.Carbon, M, Correll, CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014; 16(4): 505–524.
5.Buckley, P, Miller, A, Olsen, J, et al. 2001. When symptoms persist: clozapine augmentation strategies. Schizophr Bull. 27(4): 615–628.
6.Carbon, M, Correll, CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014; 19(Suppl 1): 38–52; quiz 35-7, 53.
7.Meltzer, HY Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin. 1997; 14(1): 1–20.
8.Samara, MT, Dold, M, Gianatsi, M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016; 73(3): 199–210.
9.Siskind, D, McCartney, L, Goldschlager, R, Kisely, S Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016; 209(5): 385–392.
10.Kane, JM, Correll, CU The role of clozapine in treatment-resistant schizophrenia. JAMA Psychiatry. 2016; 73(3): 187–188.
11.Correll, CU, Rubio, JM, Inczedy-Farkas, G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry. 2017; 74(7): 675–684.
12.Lindenmayer, J-P, Nasrallah, H, Pucci, M, et al. A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities. Schizophr Res. 2013; 147(2–3): 241–252.
13.Sommer, IE, Begemann, MJ, Temmerman, A, Leucht, S Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull. 2012; 38(5): 1003–1011.
14.Fornaro, M, Solmi, M, Perna, G, et al. Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials. Neuropsychiatr Dis Treat. 2016; 12: 1827–1836.
15.Lasser, RA, Dirks, B, Nasrallah, H, et al. Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases. Neuropsychopharmacology. 2013; 38(11); 2140–2149.
16.Curran, C, Byrappa, N, McBride, A Stimulant psychosis: systematic review. Br J Psychiatry. 2004; 185: 196–204.
17.Strakowski, SM, Sax, KW, Setters, MJ, et al. Lack of enhanced response to repeated d-amphetamine challenge in first-episode psychosis: implications for a sensitization model of psychosis in humans. Biol Psychiatry. 1997; 42(9): 749–755.
18.O’Daly, OG, Joyce, D, Stephan, KE, et al. Functional magnetic resonance imaging investigation of the amphetamine sensitization model of schizophrenia in healthy male volunteers. Arch Gen Psychiatry. 2011; 68(6): 545–554.
19.Lieberman, JA, Kane, JM, Sarantakos, S, et al. Prediction of relapse in schizophrenia. Arch Gen Psychiatry. 1987; 44: 597–603.
20.Fallon, P, Dursun, S, Deakin, B Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients. Ther Adv Psychopharmacol. 2012; 2(1): 13–22.
21.Demellweek, C, Goudie, A Behavioural tolerance to amphetamine and other psychostimulants: the case for considering behavioural mechanisms. Psychopharmacology (Berl). 1983; 80(4): 287–307.
22.Leduc, P, Mittleman, G Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. Psychopharmacology. 1995; 121: 407–427.
23.Koda, K, Ago, Y, Cong, Y, et al. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem. 2010; 114(1): 259–270.
24.Moher, D, Liberati, A, Tetzlaff, J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8: 336–341.
25.Higgins, JP, Altman, DG, Gotzsche, PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928.
26.Swerdlow, NR, Tarasenko, M, Bhakta, SG, et al. Amphetamine enhances gains in auditory discrimination training in adult schizophrenia patients. Schizophr Bull. 2016; 43(4): 872–880.
27.Goldberg, TE, Bigelow, LB, Weinberger, DR, et al. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry. 1991; 148(1): 78–84.
28.Pietrzak, RH, Snyder, PJ, Maruff, P Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia. Hum Psychopharmacol. 2010; 25(4): 353–358.
29.Daniel, DG, Weinberger, DR, Jones, DW, et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci. 1991; 11(7): 1907–1917.
30.Sanfilipo, M, Wolkin, A, Angrist, B, et al. Amphetamine and negative symptoms of schizophrenia. Psychopharmacology (Berl). 1996; 123: 211–214.
31.Friedman, JI, Carpenter, D, Lu, J, et al. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol. 2008; 28(1): 59–63.
32.Sacco, KA, Creeden, C, Reutenauer, EL, et al. Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia. Schizophr Res. 2009; 107(2–3): 332–333.
33.Martin, P, Dirks, B, Gertsik, L, et al. Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses. J Clin Psychopharmacol. 2014; 34(6): 682–689.
34.Kelly, DL, Buchanan, RW, Boggs, DL, et al. A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry. 2009; 70(4): 518–525.
35.Van Kammen, DP, Bunney, WE Jr, Docherty, JP, et al. d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. Am J Psychiatry. 1982; 139(8): 991–997.
36.Carpenter, MD, Winsberg, BG, Camus, LA Methylphenidate augmentation therapy in schizophrenia. J Clin Psychopharmacol. 1992; 12(4): 273–275.
37.Lieberman, JA, Kane, JM, Gadaleta, D, et al. 1984. Methylphenidate challenge as a predictor of relapse in schizophrenia. Am J Psychiatry. 141(5): 633–638.
38.Ball, MP, Warren, KR, Feldman, S, et al. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses. 2011; 5(1): 17–25.
39.Van Kammen, DP, Boronow, JJ Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int Clin Psychopharmacol. 1988; 3(2): 111–121.
40.Robinson, D, Mayerhoff, D, Alvir, J, et al. Mood responses of remitted schizophrenics to methylphenidate infusion. Psychopharmacology (Berl). 1991; 105(2): 247–252.
41.Sharma, RP, Javaid, JI, Pandey, GN, et al. Pharmacological effects of methylphenidate on plasma homovanillic acid and growth hormone. Psychiatry Res. 1990; 32(1): 9–17.
42.Pandurangi, AK, Goldberg, SC, Brink, DD, et al. Amphetamine challenge test, response to treatment, and lateral ventricle size in schizophrenia. Biol Psychiatry.1989; 25(2): 207–214.
43.Schulz, SC, Van Kammen, DP, Pickar, D, et al. Response of plasma beta-endorphin immunoreactivity to d-amphetamine and placebo in schizophrenic patients. Psychiatry Res. 1982; 7(2): 171–178.
44.Sharma, RP, Javaid, JI, Pandey, GN, et al. Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients. Biol Psychiatry. 1991; 30(5): 459–466.
45.Lieberman, JA, Alvir, J, Geisler, S, et al. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology. 1994; 11(2): 107–118.
46.Barch, DM, Carter, CS Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res. 2005; 77(1): 43–58.
47.Man, KK, Coghill, D, Chan, EW, et al. Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system. Transl Psychiatry. 2016; 6(11): e956.
48.Ashok, AH, Mizuno, Y, Volkow, ND, Howes, OD Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. JAMA Psychiatry. 2017; 74(5): 511–519.
49.Millan, MJ, Agid, Y, Brune, M, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 2012; 11(2): 141–168.
50.Howes, OD, Kambeitz, J, Kim, E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012; 69(8): 776–786.
51.Kambeitz, J, Abi-Dargham, A, Kapur, S, Howes, OD Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. Br J Psychiatry. 2014; 204(6): 420–429.
52.Demjaha, A, Murray, RM, McGuire, PK, et al. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012; 169(11): 1203–1210.
53.Demjaha, A, Egerton, A, Murray, RM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014; 75(5): e11–3.